Hsa_circ_0001666 promotes non-small cell lung cancer migration and invasion through miR-1184/miR-548I/AGO1 axis
2022 · Molecular Therapy — Oncolytics · 25 citations
https://doi.org/10.1016/j.omto.2022.02.011
L
Lingxin Feng
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
24
Papers
308
Citations
11
h-index
13
i10-index
Lingxin Feng is an academic researcher from Qingdao University. The author has contributed to research in topics: Lung Cancer Research Studies & Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers. The author has an h-index of 11, co-authored 21 publications.
ORCID: 0009-0001-2450-767XPapers by this author
worksPARP inhibitors in small cell lung cancer: The underlying mechanisms and clinical implications
2022 · Biomedicine & Pharmacotherapy · 18 citations
https://doi.org/10.1016/j.biopha.2022.113458
Lung Adenocarcinoma With Initially Co‐Occurring <scp>EGFR</scp> and <scp>BRAF</scp> Double Mutation: A Case Report and Literature Review
2025 · Thoracic Cancer · 0 citations
https://doi.org/10.1111/1759-7714.70031
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat